Home
drive our discovery
Finch is a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.
Human-First Discovery platform
Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.
Learn morePipeline
We are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with a candidate in late-stage clinical development for recurrent C. difficile, and candidates for inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B in pre-clinical development.
Learn moreRecent news
Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Join us
Join us in our mission to transform the lives of patients and families fighting serious medical conditions.
Learn more